Provided by Tiger Trade Technology Pte. Ltd.

IceCure Medical Ltd.

0.7300
+0.04005.80%
Post-market: 0.74000.0100+1.37%18:46 EDT
Volume:573.21K
Turnover:403.40K
Market Cap:50.34M
PE:-2.84
High:0.7368
Open:0.6762
Low:0.6200
Close:0.6900
52wk High:1.53
52wk Low:0.5401
Shares:68.96M
Float Shares:40.78M
Volume Ratio:1.28
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2573
EPS(LYR):-0.3011
ROE:-157.91%
ROA:-63.43%
PB:5.41
PE(LYR):-2.42

Loading ...

IceCure Medical Reports Record 2025 ProSense Sales and Increased U.S. Demand

Reuters
·
Jan 12

BRIEF-IceCure Medical Entered Into Amendment To Equity Distribution Agreement

Reuters
·
Jan 10

IceCure Medical Extends Equity Distribution Agreement with Maxim Group to March 2026

TIPRANKS
·
Jan 10

Icecure Medical Ltd: Entered Into Amendment to Equity Distribution Agreement- SEC Filing

THOMSON REUTERS
·
Jan 10

IceCure Medical Shareholders Approve Amended Articles of Association at January 7 Special Meeting

TIPRANKS
·
Jan 09

When Can We Expect A Profit From IceCure Medical Ltd (NASDAQ:ICCM)?

Simply Wall St.
·
Jan 08

IceCure Medical Expects Record Fourth Quarter North American Sales Following FDA Clearance

Reuters
·
Dec 17, 2025

IceCure Medical Showcases ProSense Cryoablation Data at RSNA 2025 Annual Meeting

Reuters
·
Dec 10, 2025

IceCure Medical Receives Patent Allowance in China for Next-Generation Cryogen Flow Control Technology

Reuters
·
Dec 05, 2025

IceCure Medical Reports Q3 2025 Financial Results

TIPRANKS
·
Nov 20, 2025

IceCure Medical’s Earnings Call Highlights Growth Potential

TIPRANKS
·
Nov 20, 2025

IceCure Medical Announces Receipt Of Nasdaq Minimum Bid Price Notification

Reuters
·
Nov 20, 2025

BRIEF-Icecure Reports Financial & Operational Results For The Nine Months Ended September 30, 2025

Reuters
·
Nov 19, 2025

Icecure Medical Q3 EPS $0.06 Beats $(0.05) Estimate, Sales $850.000K Beat $714.000K Estimate

Benzinga
·
Nov 19, 2025

IceCure Medical reports nine-month financial results through September 2025

Reuters
·
Nov 19, 2025

IceCure Medical Wins FDA Approval for ProSense Cryoablation System for Low-Risk Breast Cancer

Reuters
·
Nov 19, 2025

Icecure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

THOMSON REUTERS
·
Nov 19, 2025

Icecure Medical: Demand for Prosense Systems Expected to Accelerate in 2026

THOMSON REUTERS
·
Nov 19, 2025

BRIEF-Icecure's Prosense® Cryoablation System Receives Regulatory Approval In Switzerland For Indications Including Breast, Lung, Liver, And Kidney Cancer

Reuters
·
Nov 18, 2025

Icecure's Prosense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

THOMSON REUTERS
·
Nov 18, 2025